BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
UAE recalls some Nestle infant formula products, Qatar warns consumers - 2Discussion on deployment of foreign troops ongoing, two sources tell 'Post'
- 3Top Music and Dance Celebration: Which One Gets You Going?
- 4Which Carrier Do You Suggest? Vote
- 5Tyler Childers' 'Snipe Hunt' 2026 Tour: How to get tickets, presale times, prices and more
- Vote In favor of Your #1 sort of film
- Step by step instructions to Pick the Right Sunlight powered charger Type for Your Home
- Vote in favor of Your #1 sort of pie
- How Trump's marijuana executive order could change medical research landscape
- The Best Music Collections of the 10 years
- Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- German politician urges more face-to-face interaction in digital age
- We may have one thing in common with jellyfish, new research finds
- At UN climate conference, some activists and scientists want more talk on reforming agriculture
